An oncolytic adenovirus redirected with a tumor-specific T-cell receptor

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11309-11316

  Sebestyen, Zsolt ^a   De Vrij, Jeroen ^b   Magnusson, Maria ^c   Debets, Reno ^a   Willemsen, Ralph ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Got A Gene AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; EPITOPE; HLA A1 ANTIGEN; MELANOMA ANTIGEN 1; ONCOLYTIC ADENOVIRUS; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADENOVIRUS 5; ARTICLE; CELL KILLING; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN MOTIF; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; FLOW CYTOMETRY; GENETIC VECTORS; HLA-A1 ANTIGEN; HUMANS; MELANOMA; NEOPLASM PROTEINS; ONCOLYTIC VIROTHERAPY; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, VIRUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 37049014292     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0739     Document Type: Article

References (34)

1. Zinkernagel RM, Doherty PC. The discovery of MHC restriction. Immunol Today 1997;18:14-7.
2. van der BP, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
3. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8.
4. Schultz ES, Schuler-Thurner B, Stroobant V, et al. Functional analysis of tumor-specific Thcell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004;172:1304-10.
5. Couly G, Creuzet S, Bennaceur S, Vincent C, Le Douarin NM. Interactions between Hox-negative cephalic neural crest cells and the foregut endoderm in patterning the facial skeleton in the vertebrate head. Development 2002;129:1061-73.
6. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated witha MAGE antigen. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14631-8.
7. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
8. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
9. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients withrefr actory head and neck cancer. J Clin Oncol 2001;19:289-98.
10. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004;110:475-80.
11. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
12. Vellinga J, Rabelink MJWE, Cramer SJ, et al. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol 2004;78:3470-9.
13. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002;76:6893-9.
14. Gaden F, Franqueville L, Magnusson MK, et al. Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J Virol 2004;78:7227-47.
15. Henning P, Andersson KME, Frykholm K, et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers withantibody-binding domains. Gene Ther 2005;12:211-24.
16. Hong SS, Magnusson MK, Henning P, Lindholm L, Boulanger PA. Adenovirus stripping: a versatile method to generate adenovirus vectors withnew cell target specificity. Mol Ther 2003;7:692-9.
17. Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber. J Virol 2001;75:7280-9.
18. Magnusson MK, Hong SS, Henning P, Boulanger P, Lindholm L. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002;4:356-70.
19. Nilsson M, Ljungberg J, Richter J, et al. Development of an adenoviral vector system withadenov irus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004;6:631-41.
20. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
21. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997;71:8221-9.
22. Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 2001;75:2972-81.
23. Kirby I, Davison E, Beavil AJ, et al. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 1999;73:9508-14.
24. Borovjagin AV, Krendelchtchikov A, Ramesh N, Yu DC, Douglas JT, Curiel DT. Complex mosaicism is a novel approachto infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther 2005;12:475-86.
25. Willemsen RA, Debets R, Chames P, Bolhuis RLH. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003;64:56-68.
26. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther 2004;11:1234-9.
27. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 2001;8:1601-8.
28. Turatti F, Figini M, Alberti P, Willemsen RA, Canevari S, Mezzanzanica D. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med 2005;7:158-70.
29. Chames P, Willemsen RA, Rojas G, et al. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol 2002;169:1110-8.
30. Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000;7:1369-77.
31. Von Seggern DJ, Kehler J, Endo RI, Nemerow GR. Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J Gen Virol 1998;79:1461-8.
32. van Bergen BG, van der Ley PA, van Driel W, van Mansfeld AD, van der Vliet PC. Replication of origin containing adenovirus DNA fragments that do not carry the terminal protein. Nucleic Acids Res 1983;11:1975-89.
33. Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors withgene tically modified receptor specificities. Nat Biotechnol 1999;17:470-5.
34. Pecorari F, Tissot AC, Pluckthun A. Folding, heterodimeric association and specific peptide recognition of a murine αβ T-cell receptor expressed in Escherichia coli. J Mol Biol 1999;285:1831-43.